Clarity Pharmaceuticals (ASX:CU6) 3-Year Dividend Growth Rate: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
30 GF Score
Price A$2.09
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals 3-Year Dividend Growth Rate?

Clarity Pharmaceuticals ASX:CU6 -4.57% 30 3-Year Dividend Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 95 Biotechnology companies, Clarity Pharmaceuticals ranks worse than 1052630.53% on this metric.

Clarity Pharmaceuticals's Dividends per Share for the six months ended in Dec. 2025 was A$0.00.

The historical rank and industry rank for Clarity Pharmaceuticals's 3-Year Dividend Growth Rate or its related term are showing as below:

ASX:CU6's 3-Year Dividend Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Clarity Pharmaceuticals's Dividend Payout Ratio for the six months ended in Dec. 2025 was 0.00. As of today, Clarity Pharmaceuticals's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Clarity Pharmaceuticals  (ASX:CU6) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Clarity Pharmaceuticals's Dividend Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2025 )/ EPS without NRI (Q: Dec. 2025 )
=0/ -0.14734867521168
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clarity Pharmaceuticals 3-Year Dividend Growth Rate Related Terms>


ASX:CU6 vs VRTX, REGN, MRNA: 3-Year Dividend Growth Rate Comparison

For the Biotechnology subindustry, Clarity Pharmaceuticals's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clarity Pharmaceuticals 3-Year Dividend Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's 3-Year Dividend Growth Rate falls into.


ASX:CU6
30GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
3-Year Dividend Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Dividend Growth Rate of 0.00% mean?
Clarity Pharmaceuticals (ASX:CU6) has a 3-Year Dividend Growth Rate of 0.00% as of Dec. 2025. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Clarity Pharmaceuticals and its competitors. According to the industry distribution chart, Clarity Pharmaceuticals ranks #999999 out of 95 companies in the Biotechnology industry.
Is Clarity Pharmaceuticals' 3-Year Dividend Growth Rate too high?
Clarity Pharmaceuticals' current 3-Year Dividend Growth Rate is 0.00%. Based on the distribution chart, Clarity Pharmaceuticals ranks #999999 out of 95 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clarity Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' 3-Year Dividend Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clarity Pharmaceuticals ranks #999999 out of 95 companies for 3-Year Dividend Growth Rate. This places Clarity Pharmaceuticals in the lower half of its industry. The industry median 3-Year Dividend Growth Rate is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Biotechnology company?
The median 3-Year Dividend Growth Rate among Biotechnology companies is 5.20, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Clarity Pharmaceuticals and its competitors. For the Biotechnology industry, the median 3-Year Dividend Growth Rate is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clarity Pharmaceuticals's current 3-Year Dividend Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current 3-Year Dividend Growth Rate of 0.00%. The current 3-Year Dividend Growth Rate is 0.00%. Clarity Pharmaceuticals' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current 3-Year Dividend Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
30GF Score

Get the complete analysis for ASX:CU6

3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.09
Price